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Abstract
 The purpose of this study is to evaluate the diagnostic utility of whole exome 
sequencing (WES) in patients with intellectual disability (ID) or developmental delay 
(DD), and to determine which patients may be the best candidates for WES as a first-tier 
diagnostic test. The diagnostic and clinical utility of WES has emerged to be greater than 
that of karyotype and chromosomal microarray for patients with ID or DD of unknown 
etiology, which are currently recommended as first-tier diagnostic tests for these patients. 
The emergence of next generation sequencing has led to more rapid identification of rare 
and novel genetic disorders. Diagnosis of such disorders can impact medical management 
and save money. The value of this study lies in identifying which patients with ID or DD 
are more likely to receive a diagnosis via WES and therefore should be offered WES as a 
first-tier diagnostic test. This study is a retrospective review of electronic medical records 
of patients with ID/DD seen at the Greenwood Genetic Center (GGC) who have had 
WES. Patients were categorized into diagnosed, undiagnosed, or uncertain categories. 
Comparisons between patients were made based on delay types, dysmorphic features, 
birth defects, and comorbid conditions. Neither delay type, number of delays, age of 
diagnosis, or birth defects had a significant effect on likelihood of diagnosis. Patients 
with neurological features, tone differences, or eye movement disorders were 
significantly more likely to obtain a diagnosis by WES. Changes to medical management 
in diagnosed patients include referrals to new specialists, adjustments in medication 
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prescriptions, identification of contraindicated medications, and referrals to specialty 
clinics specific to disease. These data suggest that WES should be considered as a first-
tier test in any patient with ID or DD, and WES may have a higher diagnostic utility for 
those with underlying neurological disorders. 
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Clinical Diagnosis of Intellectual Disability (ID) and Developmental Delay (DD) 
 The term developmental delay (DD) is frequently used to describe a child that is 
failing to meet milestones typical to a developing child his or her age. Four common 
categories of DD include: 1) cognitive, 2) motor, 3) language and communication, and 4) 
social/emotional delay (Moeschler, Shevell, & Committee on Genetics, 2014; Petersen, 
Kube, & Palmer, 1998). Cognitive function refers to the level of cognition a person has, 
or intellectual function. Learning, thinking, and problem-solving skills are all indicative 
of cognitive development. Motor skills refer to a person’s ability to act physically. 
Examples of motor delays include not meeting milestones such as grasping, sitting, 
standing, or walking. Social/emotional delay refers to an individual’s ability to interact 
with others and respond to certain events or actions. This might include a child that does 
not recognize familiar faces when he or she should. Lastly, delays in language and 
communication refer to issues communicating with others and conveying information 
such as pointing to a specific object or the ability to speak at an age-appropriate level 
(“CDC’s Developmental Milestones | CDC,” n.d.). Any failure to meet specific age-
appropriate milestones in any of these categories can be termed developmental delay. 
There is clinical importance to the term delay, as it implies that this is a dynamic 
diagnosis that children can overcome. It is important to note that while not all delays lead 
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to life-long disabilities, they can be indicative of an underlying neurodevelopmental 
disorder (NDD) that does lead to additional long-term needs such as autism spectrum 
disorder, fragile X syndrome (FXS), and various other conditions, many of which have 
genetic etiologies.  
 Though there is no age restriction to when a person can be diagnosed with ID, 
symptoms must arise during the developmental period (American Psychiatric 
Association. & American Psychiatric Association. DSM-5 Task Force., 2013). Prior to 
when an accurate assessment of intellectual ability can be ascertained, children who have 
two or more developmental delays are thought to have global developmental delay 
(GDD). GDD may or may not manifest into ID later in life but multiple delays are 
thought to be predictors of ID, and therefore a diagnosis of ID is more indicative of 
longer term impairment (Michelson et al., 2011; Moeschler et al., 2014).  
Intellectual disability (ID) is assessed using tests of adaptive reasoning and 
standardized testing of intellectual function. Many physicians in the United States use 
criteria in the Diagnostic Statistical Manual of Mental Disorders, 5th edition (DSM-5, 
2013) to make diagnoses of ID. According to the DSM-5, ID is characterized by 
impairment of abilities that affect adaptive functioning in three different domains:  
1) “The conceptual domain includes skills in language, reading, writing, math, 
reasoning, knowledge, and memory.”  
2) “The social domain refers to empathy, social judgment, interpersonal 
communication skills, the ability to make and retain friendships, and similar capacities.”  
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3) “The practical domain centers on self-management in areas such as personal 
care, job responsibilities, money management, recreation, and organizing school and 
work tasks.” (American Psychiatric Association, 2013) 
These adaptive functioning measures are used in conjunction with standardized 
tests measuring intellectual function (learning, problem solving, and reasoning) like 
intelligence quotient (IQ) scores to diagnose ID. A person is considered intellectually 
impaired when an IQ score is two standard deviations below the mean of the population. 
This is typically an IQ score of 70 or below.  
A clinical diagnosis of ID and/or DD is often needed for patient access to 
resources such as early intervention and special education, as well as insurance coverage 
of these additional services. Pediatricians, school teachers/psychologists, or parents may 
be the first to recognize signs or symptoms of ID and DD.  Pediatricians can refer 
children to a pediatric genetics team for evaluation and consideration of genetic testing, 
as well as a developmental-behavioral pediatrician for further evaluation and clinical 
diagnosis.  Diagnosis of a genetic syndrome can allow patients to follow-up with 
necessary specialists sooner, leading to faster treatment or potential preventative therapy. 
It also allows for determination of recurrence risk and reproductive decision making. For 
these reasons, it is necessary to identify any genetic cause of ID or DD in a timely 
manner.  
Prevalence of ID and DD 
In October of 2019 the results of a study using the National Health Interview 
Survey was released. This study assessed the prevalence of developmental disabilities in 
individuals aged 3-17 years of age in the United States. Developmental disabilities are a 
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group of conditions thought to lead to lifelong impairment in physical, learning, 
language, or behavior areas. The estimated prevalence of any developmental disability, 
including attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, 
blindness, cerebral palsy, ID, learning disability (LD), moderate to profound hearing loss, 
or other developmental delay, from 2015-2017 in the United States was 17.8 %. ID 
accounted for 1.10%, LD for 7.74%, and other DD for 4.38% (Zablotsky et al., 2019).  
In addition to genetic etiologies, external factors can play a role in ID and DD, 
particularly maternal exposures, trauma, premature birth and pregnancy complications, or 
a combination of genetic and environmental factors. For these reasons, when a child 
presents with developmental delay, it is important for patients to undergo a 
comprehensive evaluation. This includes a clinical examination including an evaluation 
of head circumference, height, neurological assessment, ophthalmologic evaluation, 
otolaryngology evaluation, skin assessment, dysmorphology examination of facial 
features and extremities, and assessment of any internal malformations.  Evaluation 
should also include an assessment of the patient’s full medical history (including the 
prenatal, perinatal, postnatal, and development period) and a three-generation family 
history (Moeschler et al., 2014, 2006). 
Previous studies have determined that overall, upon evaluation, etiology can be 
identified in up to 70% of individuals with GDD.  Of this 70%, 15% are thought to be 
syndromic, and up to 40% are thought to have a genetic etiology (Miclea, Peca, Cuzmici, 
& Pop, 2015; Moeschler et al., 2014). Chromosomal abnormalities account for 25% of 
these cases, including trisomy 21, trisomy 13, trisomy 18, and structural abnormalities 
(microdeletions and microduplications). Of this population, 10% are thought to have 
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monogenic etiologies, the most common being fragile X syndrome (Miclea et al., 2015). 
These numbers are now thought to be an underestimate of the genetic etiologies, 
considering WES alone identifies genetic etiologies in 31% of patients with isolated 
neurodevelopmental disorders (Srivastava et al., 2019).  
Genetic Testing Recommendations for ID and DD 
Recommendations for genetic testing for children with intellectual disability (ID) 
and developmental delay (DD) have changed drastically with the onset of new 
technologies within the last two decades. As of 2005, the recommendation for first-tier 
testing for any child with ID or DD was cytogenetic G-banding techniques with a 
resolution of 550-banding as well as analysis for FXS (Shaffer & American College of 
Medical Genetics Professional Practice and Guidelines Committee, 2005). This was the 
first guideline set forth identifying testing necessary for any child with ID/DD despite 
whether another anomaly was present. Those guidelines also recognized that this 
cytogenetic technique does not provide enough resolution for small microdeletions and 
microduplications or chromosomal rearrangements that are known to be causative of 
ID/DD. The 2005 guidelines reserved higher resolution cytogenetic technologies for 
cases in which patients present with other anomalies such as congenital anomalies or 
dysmorphic features. In 2010, new guidelines were established recommending 
chromosomal microarray (CMA) as a first-tier genetic test for any patient with multiple 
anomalies that do not suggest a specific syndrome; or a patient with ID, DD, or autism of 
unknown origin (Manning, Hudgins, & Professional Practice and Guidelines Committee, 
2010; Miller et al., 2010). As of 2020, patients with ID/DD are still recommended CMA 
and FXS testing as the initial tests in an attempt to identify causative genetic variants. 
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The advent of next generation sequencing (NGS) is changing this view. The overall 
diagnostic rate for individuals  with ID/DD  solely using targeted NGS panels has 
increased and in some cases, even provided a corrected clinical diagnosis (Gieldon et al., 
2018). In June of 2019 a consensus statement was released by a multidisciplinary group 
entitled the “Exome Scoping Review Work Group” which states that WES consistently 
has a higher diagnostic rate than of CMA for NDDs, and proposes a strategy for first-tier 
testing with WES at the beginning of evaluation of unexplained NDDs (Srivastava et al., 
2019).  
Utility of Whole Exome Sequencing 
Whole exome sequencing (WES) utilizes NGS technology to analyze/assess the 
protein-coding portion (exons) of the genome. It has become increasingly instrumental in 
identifying rare and novel genetic disorders (Bamshad et al., 2011). WES is particularly 
useful in clinical practice when a patient presents with complex phenotypes that do not 
point to a particular syndrome of origin. Studies have shown that WES has a significantly 
higher diagnostic rate overall than that of CMA or NGS panels (Clark et al., 2018; Dillon 
et al., 2018). Typically, a patient only is offered WES after other technologies are used to 
rule out known single gene disorders, copy number variants, and chromosome 
abnormalities.  A significant proportion of patients offered WES  following other tests 
present with NDDs and the diagnostic rate by WES for these patients is estimated to be 
31% (Srivastava et al., 2019). The increase in diagnostic rate compared to CMA is 
largely attributed to the ability of WES to pick up variants at a single nucleotide 
resolution across the protein coding portion of the genome. Currently recommended first-
tier technologies such as karyotype and microarray lack this resolution. Targeted panels 
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using NGS technology to test a number of genes associated with a certain phenotype are 
also often implemented, but may not cover the entirety of the gene or risk missing a 
significant variant in a gene not included on the panel. It is also difficult to choose 
targeted panels when phenotypes appear to be unrelated or are uncommonly seen 
together. It has been determined that the broader coverage of WES increases its 
diagnostic utility compared to targeted NGS panels (Dillon et al., 2018)  
One of the many arguments against more broadly implementing WES is the 
financial burden placed on families and the healthcare system. Though more studies need 
to be done to evaluate the cost-effectiveness of WES in clinical care, it is becoming more 
commonplace in practice. The estimated cost can range worldwide between $555 and 
$5,169 for a singleton WES (Schwarze, Buchanan, Taylor, & Wordsworth, 2018). The 
preferred method of testing is WES trio analysis which includes parental studies to help 
elucidate inheritance patterns during the initial analysis, increasing those costs to $3,825-
$9,304 (Schwarze et al., 2018). Though the cost of WES is high, the collective expense of 
all other testing leading to WES can easily exceed this. Implementing WES earlier in the 
diagnostic process may eliminate other costly and unnecessary laboratory tests or other 
procedures (Córdoba et al., 2018; Monroe et al., 2016; Soden et al., 2014; Stark et al., 
2017; Valencia et al., 2015).  
 ID and DD can be seen with other congenital malformations in syndromic 
presentation or as an isolated finding. Studies have shown that the more severe phenotype 
a child presents with and the greater the number of comorbidities presented, the more 
likely a genetic diagnosis is to be made. This is particularly true of NDDs (de Ligt et al., 
2012; Fan et al., 2018). A retrospective study completed in 2018 analyzed the probability 
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of diagnosis by CMA in patients with DD and ID based on comorbid conditions (Fan et 
al., 2018). Fan et al. categorized patients based on severity of ID and found that patients 
with severe ID had a higher diagnostic rate (33%) than those of mild (19%) and moderate 
(22%) ID patients, though this was not statistically significant. This study also subdivided 
patients into categories based on common comorbidities present in this population/cohort 
and found that those with ID/DD were more likely to a obtain diagnosis via CMA when 
they also presented with congenital heart defects, facial dysmorphism, microcephaly, or 
hypotonia. Congenital heart defects had the strongest correlation. Neurodevelopmental 
disorders can range across a wide variety of phenotypes and severities. Studies have 
focused primarily on grouping children with ID/DD together as a single phenotype and 
measuring the diagnostic and clinical utility of WES in this way. Current literature 
neglects to delve into the different types of delay, and separate outcomes of WES based 
on specific delay phenotypes. These presentations can vary greatly, and severity or type 
of indication may be an indicative factor of who may be a better candidate for WES over 
others.   
Rationale of study 
 Prior concerns to implementing whole exome sequencing as a first-tier diagnostic 
test have included the lack of accessibility due to high cost. Studies have now shown that 
implementing WES first can decrease the overall cost of the diagnostic odyssey (Monroe 
et al., 2016). Previous studies that examined the diagnostic and clinical utility of WES for 
patients with ID/DD have focused on comparing WES to other testing platforms, such as 
chromosomal microarray (Clark et al., 2018). The cost of WES is decreasing and the 
ability of WES to pick up certain molecular changes over other testing strategies such as 
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microarray or targeted panels is greater (Clark et al., 2018; Dillon et al., 2018). However, 
it is the responsibility of providers to ensure that WES is being used in an appropriate 
manner. Unrestricted use could lead to inappropriate spending of healthcare dollars or 
have psychosocial implications for the patient.  
Because WES targets so many genes, there is increased chance to find a variant of 
uncertain significance (VUS) or an incidental finding. Incidental findings such as 
mutations in a gene unrelated to the indication may illicit psychosocial concerns for the 
patient (Yang et al., 2014). A VUS may be difficult to interpret or explain to a patient and 
raise concerns regarding medical management. Additionally, although the cost of WES 
has decreased it does not ensure that insurance companies will cover such testing. 
Therefore, it is necessary to identify patients who will benefit from WES over other 
forms of testing as a first-test strategy. Furthermore, studies have focused on grouping 
neurodevelopmental disorders or developmental delay together as a single phenotype, but 
few have delved into the different types of developmental delay associated with 
likelihood of diagnosis. ID and DD can span a variety of phenotypes and severities and it 
is necessary to distinguish between varying degrees and types of ID/DD as well as 
associated anomalies/comorbidities. 
Objectives 
1. Determine whether type of developmental delay or intellectual disability is 
associated with increased likelihood of a diagnosis from whole exome sequencing 
2. Assess comorbidities present and how these affect the diagnostic yield of WES  
3. Assess clinical utility of whole exome sequencing as a first-tier diagnostic test in 
children with ID/DD by reviewing changes in medical management. 
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Hypothesis 
Patients with certain types and/or multiple types of intellectual disability or 
developmental delay are more likely to obtain diagnosis by whole exome sequencing. 
The presence of certain comorbidities impacts the diagnostic yield of WES. Lastly, 
implementing WES earlier in the diagnostic testing process gives patients faster access to 
follow-up referrals and necessary resources.
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Chapter 2 
The Utility of Whole Exome Sequencing in Patients with Intellectual 
Disability and Developmental Delay as a First-tier Diagnostic Testing 
Strategy1 
Introduction 
Indications of developmental delay (DD) and intellectual disability (ID) are 
common referrals to genetics clinics. Children with developmental delays fail to meet 
milestones typical to a developing child his or her age in various categories including 
cognitive, language and communication, motor skills, and social domains. Intellectual 
disability is assessed using tests of adaptive reasoning and standardized testing of 
intellectual function. Prior to when an accurate assessment of intellectual ability can be 
ascertained, children who have two or more developmental delays are thought to have 
global developmental delay (GDD). GDD may or may not manifest into ID later in life 
but multiple delays are thought to be predictors of ID (Michelson et al., 2011; Moeschler 
et al., 2014). While not all delays lead to life-long disabilities, they can be indicative of 
an underlying neurodevelopmental disorder (NDD) that does lead to life-long disability 
such as autism spectrum disorder, fragile X syndrome (FXS), and various other 
conditions. Diagnosis of a genetic syndrome can allow patients to follow-up with 
 
1Richardson, E., Corning, K., Friez, M., & Walden, K. To be submitted to Genetics in 
Medicine 
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necessary specialists sooner, leading to faster and/or preventative treatment. It also allows 
for determination of recurrence risk and reproductive decision making. For these reasons, 
it is necessary to identify any genetic cause in a timely manner.  
The most recent guidelines set forth by the American College of Medical Genetics 
(ACMG) were released in 2010. These guidelines were established recommending 
chromosomal microarray (CMA) as a first-tier genetic test for any patient with multiple 
anomalies that do not suggest a specific syndrome; or a patient with ID, DD 
(developmental delay), or autism of unknown origin (Manning et al., 2010; Miller et al., 
2010). As of 2020, patients with ID/DD are still recommended karyotype, CMA, and 
FXS testing as the initial tests in an attempt to identify causative genetic variants. The 
advent of next generation sequencing (NGS) is changing this view due to the increased 
diagnostic rate of WES for individuals with neurodevelopmental disorders (NDDs) by 
WES. The diagnostic and clinical utility of WES has emerged to be greater than that of 
karyotype (~3%, excluding Down Syndrome and recognizable chromosome conditions) 
and CMA (~15-20%), as well as panel testing (Clark et al., 2018; Dillon et al., 2018). 
Typically, a patient is only offered WES after other technologies are used to rule out 
known single gene disorders and chromosomal variants. A significant proportion of 
patients offered WES following other tests present with NDDs and the diagnostic rate by 
WES for these patients is estimated to be 31.5% (Nambot et al., 2018). In June of 2019 a 
consensus statement was released by a multidisciplinary group entitled the “Exome 
Scoping Review Work Group” which states that WES consistently has a higher 
diagnostic rate compared to CMA for neurodevelopmental disorders, and proposes a 
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strategy for first-tier testing with WES at the beginning of evaluation of unexplained 
NDDs (Srivastava et al., 2019).  
The increase in diagnostic rate compared to other testing strategies is largely 
attributed to the ability of WES to pick up variants at a single nucleotide resolution across 
the protein coding portion of the genome. Currently recommended first-tier technologies 
such as karyotype and CMA lack this resolution. Targeted panels using NGS technology 
to test a number of genes associated with a certain phenotype are also often implemented, 
but may not cover the entirety of the gene or risk missing a significant variant in a gene 
not included on the panel. It is also difficult to choose targeted panels when phenotypes 
appear to be unrelated or are uncommonly seen together. It has been determined that the 
broader coverage of WES increases its diagnostic utility compared to targeted NGS 
panels (Dillon et al., 2018)  
 ID and DD can be seen with other congenital malformations in syndromic 
presentation or on their own as an isolated finding. Studies have shown that the more 
severe phenotype a child presents and the greater the number of comorbidities presented, 
the more likely a genetic diagnosis will be made. This is particularly true of 
neurodevelopmental disorders (de Ligt et al., 2012; Fan et al., 2018). A retrospective 
study completed in 2018 analyzed the probability of diagnosis by CMA in patients with 
DD and ID based on comorbid conditions (Fan et al., 2018). Fan et al. categorized 
patients based on severity of ID and found that patients with severe ID had a higher 
diagnostic rate (33%) than those of mild (19%) and moderate (22%) ID patients, though 
this was not statistically significant. This study also subdivided patients into categories 
based on common comorbidities present in this population/cohort and found that those 
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with ID/DD were more likely to obtain diagnosis via CMA when they also presented with 
congenital heart defects, facial dysmorphism, microcephaly, or hypotonia; congenital 
heart defects had the strongest correlation.  
 Prior concerns to implementing whole exome sequencing as a first-tier diagnostic 
test have included the lack of accessibility due to high cost. Studies have now shown that 
implementing WES first can decrease the overall cost of the diagnostic odyssey (Monroe 
et al., 2016). The cost of WES is decreasing and the ability of WES to pick up certain 
molecular changes over other testing strategies such as microarray or targeted panels is 
greater (Clark et al., 2018; Dillon et al., 2018). However, it is the responsibility of 
providers to ensure that WES is being used in an appropriate manner. Unrestricted use 
could lead to inappropriate spending of healthcare dollars. Additionally, identification of 
a variant of uncertain significance (VUS) or a secondary or incidental finding in a gene 
unrelated to the indication may raise psychosocial implications for the patient. Therefore, 
it is necessary to identify patients who will benefit from WES over other forms of testing 
as a first-test strategy. Furthermore, studies have focused on grouping 
neurodevelopmental disorders or developmental delay together as a single phenotype, but 
few have delved into the different types of developmental delay associated with 
likelihood of diagnosis. ID and DD can span a variety of phenotypes and severities and it 
is necessary to distinguish between varying degrees and types of ID/DD as well as 
associated anomalies/comorbidities. Presentations can vary greatly, and severity or type 





1. Determine whether type of developmental delay or intellectual disability is 
associated with increased likelihood of a diagnosis from whole exome sequencing 
2. Assess comorbidities present and how these affect the diagnostic yield of WES  
3. Assess clinical utility of whole exome sequencing as a first-tier diagnostic test in 
children with ID/DD by reviewing changes in medical management. 
Hypothesis 
Patients with certain types and/or multiple types of intellectual disability or 
developmental delay are more likely to obtain diagnosis by whole exome sequencing. 
The presence of certain comorbidities impacts the diagnostic yield of WES. Lastly, 
implementing WES earlier in the diagnostic testing process gives patients faster access to 
follow-up referrals and necessary resources. 
Methods 
Participants 
 Participants included in this study are patients that had a clinical evaluation at the 
Greenwood Genetic Center (GGC) and had whole exome sequencing through the 
Greenwood Diagnostic Lab. Patients must have a documented diagnosis of intellectual 
disability and/or developmental delay.  
Research Methods 
 This study is a retrospective review of electronic medical records. Cases that had 
whole exome sequencing in the years 2017 or 2018, with an indication of developmental 
delay or intellectual disability were considered for inclusion. A total of 111 cases from 
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2017 and 142 cases from 2018 were reviewed. Cases were included from two consecutive 
years to capture a representative sample across a longer period of time. Of the 253 cases  
reviewed, eight were excluded for lack of additional information.  
 
Figure 2.1. Methods by which cases were filtered to assess for features. Cases included in 
the blue boxes were assessed for dysmorphic features, birth defects, and comorbid 
conditions. Cases included in the green boxes were additionally assessed for different 
types of delay. 
Patient records were reviewed to collect all relevant clinical, medical, and 
laboratory data including, primary indication for genetics consultation, detailed 
phenotypic data, and laboratory test results. Records were reviewed to ascertain type of 
developmental delay present, for example: cognitive, motor, social/emotional, language 
delay, or multiple delays. This information was determined by reviewing behavioral tests 
from professionals such as developmental pediatricians or psychologists, any school 
records available, and the assessment of the medical geneticist as documented in the 
17 
clinic notes. Intellectual Quotient (IQ) scores were recorded for patients when they were 
available.  
Patients were categorized into three result groups: diagnosed, undiagnosed, and 
uncertain. The diagnosed group consists of patients that received a result from WES that 
explained their clinical features. These results were delivered as a diagnosis by the 
physician and patients are being managed accordingly; this includes cases with 
pathogenic and likely pathogenic alterations as well as 11 cases who received a variant of 
uncertain significance (VUS). The undiagnosed patients received results that did not 
explain their condition. These results included those with a pathogenic mutation or 
variant of uncertain significance in a gene that did not fit the phenotypic description. It 
also included identification of a single variant in a gene that must be present in trans with 
a second pathogenic variant to be disease-causing. More commonly, in the undiagnosed 
cohort, no significant variants were identified. Patients were considered part of the 
uncertain category if a VUS was identified in a gene that is suggestive of the clinical 
picture, but more evidence is needed to definitely confirm the diagnosis.  
Other phenotypic data was collected and organized into three categories 1) 
dysmorphic features, 2) birth defects, and 3) comorbid conditions. Dysmorphic features 
include physical differences documented in notes from clinic visits such as differences in 
head shape, tonicity, facial features, stature, hands, and feet. Birth defects include 
congenital anomalies such as structural defects in the brain, heart, and genitalia. 
Comorbid conditions include additional diagnoses and conditions such as autism, 
attention deficit hyperactivity disorder (ADHD), seizures, coordination/balance issues, 
premature birth, vision loss, and hearing loss. For a full list of conditions included in 
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these categories see Appendix A. Categories were analyzed to determine if having any of 
these features affected the likelihood of receiving a likely pathogenic or pathogenic 
variant by WES. For the sake of analysis of phenotypic data including different 
categories of developmental delay, dysmorphic features, birth defects, and comorbid 
conditions, the 11 patients with a VUS in the diagnosed category, as well as patients with 
an uncertain result (42) were removed from this portion of the study. This left 192 cases 
that were assessed for these features. Additionally, no phenotypic data was analyzed if 
that feature was present in less than 5 patients total, or if a feature was present in the 
undiagnosed category of patients, but was not present in the diagnosed category. There 
were no features present in patients of the diagnosed category that were not present in 
patients of the undiagnosed category. For this part of the analysis, patients were placed 
into two groups.  The patients categorized as diagnosed with a pathogenic or likely 
pathogenic result are referred to as the P/LP population and patients for whom no 
significant variants were identified and are considered undiagnosed are the no significant 
variants population (No Sig. Variants, or NSV.) 
The impact of a molecular diagnosis on medical management changes was also 
assessed. No identifying patient information, including name, medical record number, or 
date of birth, were recorded when data was collected. Each patient was assigned a study-
specific identifier.  
Statistical Analysis and Statistical Methods 
 The data collected required both quantitative and qualitative analysis to reach the 
objectives of this study. The majority of the data collected were categorical, and therefore 
descriptive statistics (percentages, frequencies, and odds ratios) were calculated. To 
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compare categorical variables, Pearson’s chi-square test for independence was used. 
Statistical significance was determined from a two-tailed exact value. For quantitative 
analysis to compare means, a two-tailed student’s t-test was used. For descriptive 
statistical analysis, Microsoft Excel was used. Microsoft Excel was also used as a 
database for the collected information, and de-identified data was exported to IBM 
Statistical Package for Social Sciences (SPSS) version 25 for quantitative analysis as well 
as for calculation of odds ratios with 95% confidence intervals.  Figures and tables were 
constructed using Microsoft Excel, Microsoft PowerPoint, and GraphPad Prism version 
8.3.1.  
Results 
The overall diagnostic rate was determined for this patient population, the results 
are displayed in Figure 2.2. Of the 245 patients included in this study, 77 received a 
diagnosis (31.4%). Eleven of those patients have a variant(s) of uncertain significance 
(VUS) that were delivered to the family as a diagnosis and are being medically managed 
for the genetic syndrome identified. The remaining 66 patients received a definitive 
diagnosed by a likely pathogenic or pathogenic variant(s) (P/LP Population). Forty-two 
patients (17.1%) had uncertain results, which consisted of a VUS that fits the clinical 
picture and is suspected to be causative but more information is needed to confirm a 
diagnosis. For the remaining 126 patients (51.4%), no variants identified were thought to 
be significant (No Sig. Variants or NSV Population). 
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Figure 2.2. Overall Diagnostic Rate. Overall diagnostic rate of WES in this study’s 
patient population.  
Age of the patient when the WES report was disclosed from the laboratory to the 
physician was recorded. A comparison of the mean age of patients at the date of WES 
report in diagnosed, undiagnosed, and uncertain categories revealed no significant 
difference between result groups (Figure 2.3). 
 
Figure 2.3. Mean age at date of WES report. Comparison of the mean age of patients at 
the date of WES report in Diagnosed (8.13y) vs. Undiagnosed (9.71y) and Uncertain 
(8.95y) WES results. A two-tailed student’s t-test revealed no significant difference 
between result groups. 
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 IQ scores were recorded from records when available. This study revealed no 
significant difference between patient IQ scores in each result category.  
 
Figure 2.4. Average IQ per WES result category. Comparison of known IQ scores in 
patients with Diagnosed, Undiagnosed, and Uncertain WES results. A student’s t-test 
(two tailed) revealed no significant difference in IQ score between result groups.  
The following data was assessed excluding patients in the diagnosed category that 
had a VUS and all patients in the uncertain result category. Patients who received a 
diagnosis with a pathogenic or likely pathogenic variant were placed in the P/LP 
Population category. Patients for whom WES was not diagnostic because no significant 
variants were identified were placed in the No Significant Variants (No Sig. Variants or 
NSV) category. Odds ratios were determined for how likely a patient is to be in the NSV 
category if particular features were not present. 
Number of delays, prevalence of each type of delay, and odds ratios were 
assessed for this patient population (Figures 2.5-2.7). Neither type of delay nor number of 
delays between the P/LP and NSV populations were significantly different.  
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Figure 2.5. Number of delays per patient population. The majority of patients studied for 
delay type had delays in all four areas assessed.  
 
Figure 2.6. Prevalence of delay in patient population. The percentage of patients with a 
specific type of delay in each result population (i.e. 68% of the Total Population (P/LP + 
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Odds Ratios for Delay Type
Odds Ratio
 
Figure 2.7. Odds ratios for delay type. Odds ratios with 95% confidence intervals for 
being in the NSV Population if a patient does not have a particular type of delay. 
Pearson’s chi-squared test revealed there was no significant difference between delay 
type in determining odds of being in the NSV category. 
Different dysmorphic features (Figures 2.8-2.9), birth defects (Figures 2.10-2.11), 
and comorbid conditions (Figures 2.12-2.13) were assessed among the P/LP and NSV 
patient populations. Prevalence of the feature in the P/LP and total populations (P/LP + 
NSV populations) are displayed, as well as odds ratios for being in the NSV Population 
category if a particular feature is not present in a patient. Chi-squared analysis revealed 
the only significant features were differences in tonicity (primarily hypotonia), hypotonia 
alone, and eye movement disorders. Neurological features were then assessed separately 
(Figures 2.14-2.15). Patients who did not exhibit any neurological feature were 2.7x more 
likely to be in the NSV category (p=0.011). Patients who did not have a tone difference 
were 2.1x more likely to be in the NSV category (p=0.019). Patients who did not exhibit 
hypotonia were 1.89x more likely to be in the NSV category (p=0.055). Lastly, patients 




Figure 2.8. Prevalence of dysmorphic features. Prevalence of dysmorphic features in the 
P/LP Population and Total Population. 














Odds  Ratios for Dysmorphic Features
Odds Ratio
 
Figure 2.9. Odds ratios for dysmorphic features. Odds ratios with 95% confidence 
intervals for being in the NSV Population if a patient does not have a particular 
dysmorphic feature. None of the features listed were statistically significant. 
25 
 
Figure 2.10. Prevalence of birth defects. Prevalence of birth defects in the P/LP 
Population and Total Population. 








Odds  Ratios for Birth Defects
Odds  Ratio
 
Figure 2.11. Odds ratios for birth defects. Odds ratios with 95% confidence intervals for 
being in the NSV Population if a patient does not have a particular birth defect. None of 
the features listed were statistically significant. 
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Figure 2.12. Prevalence of comorbid conditions. Prevalence of comorbid conditions in 
the P/LP Population and Total Population. 




















Odds Ratios for Comorbid Conditions
Odds  Ratio
 
Figure 2.13. Odds ratios for comorbid conditions. Odds ratios with 95% confidence 
intervals for being in the NSV Population if a patient does not have a particular 
comorbidity. None of the features listed were statistically significant. 
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Figure 2.14. Prevalence of neurological features. Prevalence of features than can be 
indicative of underlying neurological disorders in the P/LP and Total patient populations.   










Odds Ratios for Neurological Features
Odds  Ratio
 
Figure 2.15. Odds ratios for neurological features. Odds ratios with 95% confidence 
intervals for being in the NSV Population if a patient does not have a neurological 
feature. *Features which were statistically significant based on two-tailed exact p-values 
of ≤0.05 using Pearson’s chi-squared analysis.  
Medical management changes were assessed for all 77 of the patients who 
received a diagnosis from WES sequencing results. Of those patients, 25 patients 
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received a new referral immediately after diagnosis. Four patients were referred to 
specialty clinics for their specific syndrome for expert care. Two patients were prescribed 
additional medications, and three were instructed to avoid contraindicated medications. 
Recurrence risk was determined for 69 of these families.  
Secondary and incidental findings were discovered in 12 patients in the genes 
listed in Figure 2.16.  
Gene Classification Associated condition 
APOB Likely pathogenic Familial hypercholesterolemia 
ATM Likely pathogenic Breast cancer and possibly other cancers 
ATM Likely pathogenic Breast cancer and possibly other cancers 
BRIP1 Pathogenic Ovarian cancer 
DSP Likely pathogenic Arrhythmogenic right ventricular dysplasia 
KCNH2 Likely pathogenic Type II long QT syndrome, Romano Ward Syndrome 
PALB2 Pathogenic Breast cancer and other cancers 
PALB2 Likely pathogenic Breast cancer and other cancers 
RAD51C Pathogenic Ovarian cancer 
RAD51D Likely pathogenic Ovarian cancer and possibly breast cancer 
RAD51D Likely pathogenic Ovarian cancer and possibly breast cancer 
SPAST Likely pathogenic Hereditary spastic paraplegia 4 (SPG4)* 
 
Figure 2.16. Secondary and incidental findings revealed by WES. These findings do not 
fit the patient’s clinical picture at the time WES was run, but imply health risks that could 
develop later and patients should be monitored accordingly. 
Lastly, age of each patient on the date of the WES report was recorded for each of 
the patients in this study. Of these patients, 35.4% were under the age of five years old at 
the date of the WES report disclosure to the physician, while 64.2% were under the age 
of 10 years old. For 163 patients, the age of the patient at the date the CMA results were 
recorded. The average age of a patient at CMA return of results was 6.61 years old, and 
the average age at return of WES results was 9.17 years old; 20% of patients had less 
than six months between return of the CMA result and return of the WES result.  
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Discussion 
Overall Diagnostic Rate 
This study revealed an overall diagnostic rate of 32% (Figure 2.2); a rate similar 
to those previously reported for patients with neurodevelopmental disorders (Srivastava 
et al., 2019). This does not include the 17% of patients who received results that may be 
diagnostic and require some functional studies to verify pathogenicity (uncertain results). 
These uncertain results are variants of uncertain significance (VUS) in genes implicated 
in diseases that may fit the clinical picture of the patient, but insufficient evidence about 
the variant itself is available to deem it pathogenic. Some of the variants discovered by 
these studies are being evaluated by functional studies through GGC’s research division, 
or contributed to publications of novel genetic disorders. Further studies, such as 
functional analysis, will work to verify pathogenicity of particular variants in these 
patients, resulting in confirmed diagnoses for these individuals and will contribute to 
helping diagnose others presenting with similar phenotypes among undiagnosed patients 
all over the world.  
Age of diagnosis 
The average age of patients at return of WES results did not vary significantly 
between result groups (Figure 2.3). The majority of patients in this study were under the 
age of 10 years old at the date WES results were returned (64%), with 35% of patients 
under the age of 5 years old. It was initially hypothesized that older patients, who have 
likely already exhausted testing options may have a higher diagnostic rate by WES. This 
study is limited by the fact that most of the individuals included, regardless of age, have 
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already had at minimum a karyotype and a microarray, ruling out diagnoses from 
structural chromosome abnormalities, microdeletions, and microduplications. These 
results support that once these abnormalities have been ruled out, it is a logical next step 
to move to WES, regardless of age of the patient.  
Role of IQ in diagnostic rate 
Some have theorized that more severe forms of intellectual disability are more 
likely to be genetic (Ropers, 2010). This study did not reveal a statistically significant 
difference on the diagnostic rate based on IQ score (Figure 2.4). However, the relatively 
small sample size that had a documented IQ may not be enough to make this 
determination. A large proportion of patients included in this study were under the age of 
5 years old, and thus were not of appropriate age to assess IQ. It is also important to note 
that IQ scores can vary by testing strategy and change as individuals age. The IQ scores 
collected during this study were tested at various ages and by various testing strategies, 
for which we were unable to control.  
Role of delay type in diagnosis 
A goal of this study was to assess the likelihood of diagnosis based on type of 
delay or number of delays present in an individual. Often, children present early on with 
a single delay, such as language and communication, and others may become apparent 
later in development. Assessment of both the number of delays present in each patient in 
each result category (Figure 2.5) and the percentage of patients with of each type of delay 
in each result category (Figure 2.6) revealed no significant effect on likelihood of 
diagnosis based on type of delay or number of delays present in an individual. Likewise, 
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the odds ratios for the likelihood of being in the category of patients without a significant 
variant identified (No Sig. Variants) if a patient does not have a particular delay, is not 
significant (Figure 2.7). Each delay type revealed an odds ratio close to one, indicating no 
difference between delay type and whether patients were in the P/LP or NSV categories. 
These results indicate that individuals with any type or number of delays present should 
be considered for WES. The results of this study may be limited by the relatively small 
sample size for individuals with fewer than four delays. The majority of patients had a 
delay in all four categories assessed.  It is important to note that all patients were 
evaluated by medical geneticists, and have essentially been preselected as good 
candidates for WES where a diagnosis may be likely. Many patients were seen within the 
first two years of development, when certain delays may be difficult to assess without 
standardized testing strategies. These testing strategies are not implemented in the short 
time allotted for a genetics evaluation. Similarly, there are long wait-lists for 
developmental pediatric evaluations where these delays are formally evaluated. Though 
developmental pediatric assessments were reviewed, records were not always available or 
patients may not have been seen by the time of review. Therefore, those with a single 
delay or fewer delays may have had delays in all areas, but these delays were not 
apparent at the time. Given the long wait times for developmental pediatric assessments 
this data suggests that all patients with developmental delays are good candidates for 




Association of dysmorphic features, birth defects and comorbid conditions with 
diagnostic rate 
A large number of dysmorphic features, birth defects, and comorbid conditions 
were present in the patients included in this study (Figures 2.8-2.15). Patients 
recommended for WES typically have complex phenotypes that do not point to a 
particular syndrome. Given there were no patients included in this study that did not have 
any additional features in at least one of the categories studied, this population has an 
inherent bias for more complex phenotypes. Overall, the most common features were 
differences in tonicity (primarily hypotonia), dysmorphic head size/shape (primarily 
microcephaly), dysmorphic facial features, and autism; each of which were present in 
greater than 30% of the total population of patients. The statistically significant features 
were differences in tone (primarily hypotonia) and eye movement disorders (nystagmus, 
strabismus, exotropia, esotropia). Hypotonia is a common referral for genetic evaluation. 
Both hypotonia and eye movement disorders are common features of underlying 
neurological disorders, many of which can be genetic. For these reasons, neurological 
features were further assessed for this cohort. Figure 2.14 displays other neurological 
features present in this cohort. Tone differences were further assessed by addressing 
patients with hypotonia specifically. A chi-squared analysis revealed that any tone 
difference, hypotonia, eye movement disorder, or any of these neurological features 
assessed were statistically significant (Figure 2.15). Thus, these data support previous 
knowledge that WES has higher diagnostic potential for neurodevelopmental disorders, 
specifically those with neurological features in addition to developmental delays. 
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Changes to Medical Management 
For each of the 77 diagnosed patients, clinic notes were reviewed for changes to 
medical management following diagnosis. Many patients were already followed by 
several specialists, and the geneticist did not feel it necessary to make further referrals. 
For these patients where disease associated phenotypes were not a current concern, 
pediatricians should be aware of the newly diagnosed condition to monitor for future 
concerns. For 25 patients, a referral to another specialist was made immediately after 
diagnosis. These specialty referrals included: nephrology, ophthalmology, cardiology, 
audiology, neuropsychology, dentistry, endocrinology, metabolic, developmental 
pediatrics, orthopedics, otolaryngology, and neurology. An additional four patients were 
referred to specialty clinics for their specific syndrome for expert care. Two patients were 
prescribed additional medications, and three were instructed to avoid contraindicated 
medications.  
Aside from the important changes to medical management that were identified, 
there were also important implications to family members. Many patients were children 
of parents who sought to have more children and would benefit from a recurrence risk 
estimate. For these families, finding the cause of their child’s symptoms holds important 
information for future pregnancies and reproductive decision making. This allows for 
prenatal testing, preimplantation genetic testing, and can aid families in decisions 
regarding use of egg or sperm donors, or adoption. Recurrence risk was determined for 
69 of the 77 families. Lack of one or both parental samples made it impossible to 
determine the recurrence risk for the remaining eight patients. Obtaining a diagnosis can 
also have positive psychosocial implications for families. Studies have shown that parents 
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who receive a diagnosis for their child have better coping mechanisms, are more aware of 
their child’s particular needs, and have the opportunity to reach out to families affected 
by the same or similar conditions (Krabbenborg et al., 2016).   
Secondary and Incidental Findings 
There are many ethical considerations in implementing WES, especially in young 
children. Proper consent should be given, and families should be informed of the 
possibility for uncertain, secondary, and incidental findings. Secondary and incidental 
findings were identified in 12 patients in this study (Figure 2.16.) Though these findings 
do not offer an explanation for the clinical picture for which the WES was indicated, they 
have important management implications for the patient and family members. Many 
mutations discovered were in genes related to hereditary cancer syndromes that do not 
have medical management implications until adulthood. Identifying these mutations in 
young children reduces patient autonomy, and parents should be properly informed of 
this potential consequence. On the other hand, identification of these mutations also 
allows for testing of other family members, increased screening earlier in life and is 
potentially lifesaving. 
WES as a First-tier Test 
WES is not currently a recommended first-tier test for any of the patients included 
in this study, therefore each of the patients diagnosed in this study received numerous 
laboratory tests before WES. For many of these patients, changes to medical management 
would have been implemented sooner had WES been ordered sooner. It is clear that some 
physicians are already turning to WES quickly after karyotype and CMA when these 
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first-tier tests do not reveal a cause for symptoms. At least 20% of patients received a 
result from WES less than six months after return of CMA results. For some of these 
patients, CMA and WES were ordered at the same time. Though the diagnostic yield 
varies between CMA and WES, it is clear that understanding both copy number variants 
(CNVs) and single nucleotide variants is important and helpful in diagnosing individuals 
with neurodevelopmental disorders. For several patients who received a result revealing a 
pathogenic variant in a gene implicated in an autosomal recessive disorder, without a 
second variant in trans, CMA was utilized to determine if there was a CNV on the 
opposite chromosome.  
Costs are not only decreasing for WES, but laboratories are working quickly to 
implement whole genome sequencing (WGS) in the clinical setting. Additionally, many 
patients had a finding on CMA, such as a deletion or duplication considered a VUS, or an 
inherited variant. It is unclear whether these findings are significant, or if the combination 
of these variants with other types of variants may play a role for a polygenic effect on the 
phenotype. We may learn more about how these variants interact with each other in the 
future as we learn more about genetics in general. As the costs decrease, and analysis 
tools improve, WGS could be used as a single test in place of CMA and WES. WGS has 
the capability of picking up copy number variants and single-nucleotide variants, as well 
as variants missed by WES like deep intronic variants and variants in regulatory 
elements.  
Healthcare providers consider many factors in trying to select the best test for 
their patients.  These data indicate that it is reasonable and beneficial to consider WES as 
a first-tier test for patients with developmental delays. Additionally, this study supports 
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the idea that patients with a variety of additional features like dysmorphic features, 
congenital anomalies, and comorbid conditions benefit from implementing WES sooner 
in the diagnostic process. This would allow for earlier implementation of treatment and 
potentially increased screening of comorbid disorders. It would allow for increased 
access to services at earlier ages, and save families money from uninformative tests. 
Giving families answers could lead to reproductive decision making such as 
preimplantation genetic testing, egg or sperm donors, or adoption. Knowing the genetic 
risks could lead to prenatal testing, prenatal and perinatal management of any future 
pregnancies.  
Limitations 
There are limitations to consider when interpreting the results of this study. The 
phenotypic information collected in medical records did not always reflect what was 
included on the test requisition and used for WES analysis. A key element to analysis of 
variants discovered by WES is knowing all relevant clinical information. This 
information is taken into account to determine the pipeline through which variants are 
filtered. If information recorded in this study was not present on the test requisition form, 
it is likely that this information was not used during analysis, and causative variants may 
have been overlooked. This study also neglects to address that these features typically 
present as a constellation of features in a patient. Most of the patients used to study the 
different effects of type of delay and various co-occurring features had multiple features 
that did not fit into a single category. Additionally, patients had other features that were 
not addressed in this study primarily due to the low population of patients in this study 
with that particular feature.  
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Types of delay present in a child were often recorded based on experience and 
expertise of the medical geneticist using only what was discussed in clinic visit notes. 
Many children had yet to be evaluated by a developmental pediatrician, or records from 
those visits and standardized tests were not available. When testing records were 
available, the most recent evaluations may not have been included. There were cases 
where clinic notes were compared to the Denver Developmental Milestones to determine 
if a delay was present if it was not explicitly mentioned in the clinic note. Though these 
milestones are used by most pediatricians to determine the developmental progress of a 
child, it is out of the scope of practice of a genetic counselor to make these 




Developmental delays are fairly common in children. Though they do not mean 
that a child will have life-long needs, it is necessary to determine if there is an underlying 
medical condition that needs to be addressed. Earlier diagnosis has numerous benefits in 
that it could lead to faster and/or preventative treatment, increased screening, and 
financial savings. Determination of inheritance pattern of genetic diseases could lead to 
reproductive decision-making such as family planning, use of egg or sperm donors, 
preimplantation genetic testing, or adoption. For families who choose to have children 
knowing their genetic risk, it could allow for prenatal testing and change in medical 
management prenatally and perinatally. It may also give families time to prepare 
emotionally and gather what they might need to care for a child with special needs.  
Genetic testing options have evolved rapidly in the past decade. Karyotype, CMA, 
and FXS testing are currently the recommended genetic tests for any patient presenting 
with developmental delays or intellectual disability (Manning et al., 2010; Miller et al., 
2010). Studies have shown that WES has an increased diagnostic rate compared to each 
of these tests for individuals with NDDs who have had other anomalies ruled out from 
the recommended first-tier testing options (Srivastava et al., 2019). This study supports 
those previously determined diagnostic rates, with an overall diagnostic rate of 32%. The 
majority of patients included in this study had developmental delays in each of the four 
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categories assessed. These patients also had at least one additional feature in dysmorphic 
features, congenital anomalies, or comorbid conditions. Neither type of delay or age of 
the patient had a significant effect on the likelihood of diagnosis. For the majority of the 
additional features assessed, there was no significant difference in likelihood of diagnosis 
for patients who had that feature versus those who did not. The exceptions being patients 
with any neurological feature, tone differences, or eye movement disorders. This study 
suggests that WES is a good test for any individual with a history of developmental 
delays or with any additional feature. It may have higher diagnostic potential for patients 
with underlying neurological disorders, though more studies are necessary to definitively 
make this conclusion.  
In our patient population, providers have already started to order WES quickly 
after, or in tandem to CMA. The financial burden placed on patients can be large as 
insurance companies are not necessarily covering such tests. Studies like this, 
establishing WES as a first-tier test may provide insurance companies evidence to show 
that covering such tests is beneficial to the patient and the insurance provider, by limiting 
the number of uninformative tests performed. As quickly as WES has become more 
commonplace in practice, WGS is also quickly emerging in clinical care. Despite the 
difference in diagnostic rate, it is clear that CMA and WES have their place in clinical 
care of patients with DD and/or ID. It may be that as WGS becomes faster and more 
affordable, this test will come to replace both CMA and WES due to its increased 




American Psychiatric Association., & American Psychiatric Association. DSM-5 Task 
Force. (2013). Diagnostic and statistical manual of mental disorders : DSM-5. 
American Psychiatric Association. 
American Psychiatric Association. (2013). Intellectual Disability [Fact Sheet]. Retrieved 
from https://www.psychiatry.org/File 
Library/Psychiatrists/Practice/DSM/APA_DSM-5-Intellectual-Disability.pdf 
Bamshad, M. J., Ng, S. B., Bigham, A. W., Tabor, H. K., Emond, M. J., Nickerson, D. 
A., & Shendure, J. (2011). Exome sequencing as a tool for Mendelian disease gene 
discovery. Nature Publishing Group, 12, 745. https://doi.org/10.1038/nrg3031 
CDC’s Developmental Milestones | CDC. (n.d.). Retrieved May 14, 2019, from 
https://www.cdc.gov/ncbddd/actearly/milestones/index.html 
Clark, M. M., Stark, Z., Farnaes, L., Tan, T. Y., White, S. M., Dimmock, D., & 
Kingsmore, S. F. (2018). Meta-analysis of the diagnostic and clinical utility of 
genome and exome sequencing and chromosomal microarray in children with 





Córdoba, M., Rodriguez-Quiroga, S. A., Vega, P. A., Salinas, V., Perez-Maturo, J., 
Amartino, H., … Kauffman, M. A. (2018). Whole exome sequencing in 
neurogenetic odysseys: An effective, cost- and time-saving diagnostic approach. 
PLOS ONE, 13(2), e0191228. https://doi.org/10.1371/journal.pone.0191228 
de Ligt, J., Willemsen, M. H., van Bon, B. W. M., Kleefstra, T., Yntema, H. G., Kroes, 
T., … Vissers, L. E. L. M. (2012). Diagnostic Exome Sequencing in Persons with 
Severe Intellectual Disability. New England Journal of Medicine, 367(20), 1921–
1929. https://doi.org/10.1056/NEJMoa1206524 
Dillon, O. J., Lunke, S., Stark, Z., Yeung, A., Thorne, N., Gaff, C., … Tan, T. Y. (2018). 
Exome sequencing has higher diagnostic yield compared to simulated disease-
specific panels in children with suspected monogenic disorders. European Journal 
of Human Genetics, 26(5), 644–651. https://doi.org/10.1038/s41431-018-0099-1 
Fan, Y., Wu, Y., Wang, L., Wang, Y., Gong, Z., Qiu, W., … Yu, Y. (2018). 
Chromosomal microarray analysis in developmental delay and intellectual disability 
with comorbid conditions. BMC Medical Genomics, 11(1), 49. 
https://doi.org/10.1186/s12920-018-0368-4 
Gieldon, L., Mackenroth, L., Kahlert, A.-K., Lemke, J. R., Porrmann, J., Schallner, J., … 
Rump, A. (2018). Diagnostic value of partial exome sequencing in developmental 





Krabbenborg, L., Vissers, L. E. L. M., Schieving, J., Kleefstra, T., Kamsteeg, E. J., 
Veltman, J. A., … Van der Burg, S. (2016). Understanding the Psychosocial Effects 
of WES Test Results on Parents of Children with Rare Diseases. Journal of Genetic 
Counseling, 25(6), 1207–1214. https://doi.org/10.1007/s10897-016-9958-5 
Manning, M., Hudgins, L., & Professional Practice and Guidelines Committee. (2010). 
Array-based technology and recommendations for utilization in medical genetics 
practice for detection of chromosomal abnormalities. Genetics in Medicine : Official 
Journal of the American College of Medical Genetics, 12(11), 742–745. 
https://doi.org/10.1097/GIM.0b013e3181f8baad 
Michelson, D. J., Shevell, M. I., Sherr, E. H., Moeschler, J. B., Gropman, A. L., & 
Ashwal, S. (2011). Evidence Report: Genetic and metabolic testing on children with 
global developmental delay: Report of the quality standards Subcommittee of the 
American Academy of Neurology and the Practice Committee of the Child 
Neurology Society. Neurology, 77(17), 1629–1635. 
https://doi.org/10.1212/WNL.0b013e3182345896 
Miclea, D., Peca, L., Cuzmici, Z., & Pop, I. V. (2015). Genetic testing in patients with 
global developmental delay / intellectual disabilities. A review. Clujul Medical. 






Miller, D. T., Adam, M. P., Aradhya, S., Biesecker, L. G., Brothman, A. R., Carter, N. P., 
… Ledbetter, D. H. (2010). Consensus Statement: Chromosomal Microarray Is a 
First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities 
or Congenital Anomalies. The American Journal of Human Genetics, 86(5), 749–
764. https://doi.org/10.1016/J.AJHG.2010.04.006 
Moeschler, J. B., Shevell, M., & Committee on Genetics, C. O. (2014). Comprehensive 
evaluation of the child with intellectual disability or global developmental delays. 
Pediatrics, 134(3), e903-18. https://doi.org/10.1542/peds.2014-1839 
Moeschler, J. B., Shevell, M., Schaefer, G. B., Bull, M. J., Enns, G. M., Gruen, J. R., … 
Spire, P. (2006). Clinical genetic evaluation of the child with mental retardation or 
developmental delays. Pediatrics, 117(6), 2304–2316. 
https://doi.org/10.1542/peds.2006-1006 
Monroe, G. R., Frederix, G. W., Savelberg, S. M. C., de Vries, T. I., Duran, K. J., van der 
Smagt, J. J., … van Haaften, G. (2016). Effectiveness of whole-exome sequencing 
and costs of the traditional diagnostic trajectory in children with intellectual 
disability. Genetics in Medicine, 18(9), 949–956. 
https://doi.org/10.1038/gim.2015.200 
Nambot, S., Thevenon, J., Kuentz, P., Duffourd, Y., Tisserant, E., Bruel, A.-L., … 
Group, O. P. (2018). Clinical whole-exome sequencing for the diagnosis of rare 
disorders with congenital anomalies and/or intellectual disability: substantial interest 
of prospective annual reanalysis. Genetics in Medicine, 20(6), 645–654. 
https://doi.org/10.1038/gim.2017.162 
44 
Petersen, M. C., Kube, D. A., & Palmer, F. B. (1998). Classification of developmental 
delays. Seminars in Pediatric Neurology, 5(1), 2–14. https://doi.org/10.1016/S1071-
9091(98)80012-0 
Ropers, H. H. (2010). Genetics of Early Onset Cognitive Impairment. Annual Review of 
Genomics and Human Genetics, 11(1), 161–187. https://doi.org/10.1146/annurev-
genom-082509-141640 
Schwarze, K., Buchanan, J., Taylor, J. C., & Wordsworth, S. (2018). Are whole-exome 
and whole-genome sequencing approaches cost-effective? A systematic review of 
the literature. Genetics in Medicine, 20(10), 1122–1130. 
https://doi.org/10.1038/gim.2017.247 
Shaffer, L. G., & American College of Medical Genetics Professional Practice and 
Guidelines Committee. (2005). American College of Medical Genetics guideline on 
the cytogenetic evaluation of the individual with developmental delay or mental 
retardation. Genetics in Medicine : Official Journal of the American College of 
Medical Genetics, 7(9), 650–654. 
https://doi.org/10.109701.gim.0000186545.83160.1e 
Soden, S. E., Saunders, C. J., Willig, L. K., Farrow, E. G., Smith, L. D., Petrikin, J. E., … 
Kingsmore, S. F. (2014). Effectiveness of exome and genome sequencing guided by 
acuity of illness for diagnosis of neurodevelopmental disorders. Science 




Srivastava, S., Love-Nichols, J. A., Dies, K. A., Ledbetter, D. H., Martin, C. L., Chung, 
W. K., … Miller, D. T. (2019). Meta-analysis and multidisciplinary consensus 
statement: exome sequencing is a first-tier clinical diagnostic test for individuals 
with neurodevelopmental disorders. Genetics in Medicine, 21(11), 2413–2421. 
https://doi.org/10.1038/s41436-019-0554-6 
Stark, Z., Schofield, D., Alam, K., Wilson, W., Mupfeki, N., Macciocca, I., … Gaff, C. 
(2017). Prospective comparison of the cost-effectiveness of clinical whole-exome 
sequencing with that of usual care overwhelmingly supports early use and 
reimbursement. Genetics in Medicine, 19(8), 867–874. 
https://doi.org/10.1038/gim.2016.221 
Valencia, C. A., Husami, A., Holle, J., Johnson, J. A., Qian, Y., Mathur, A., … Zhang, K. 
(2015). Clinical Impact and Cost-Effectiveness of Whole Exome Sequencing as a 
Diagnostic Tool: A Pediatric Center’s Experience. Frontiers in Pediatrics, 3, 67. 
https://doi.org/10.3389/fped.2015.00067 
Yang, Y., Muzny, D. M., Xia, F., Niu, Z., Person, R., Ding, Y., … Eng, C. M. (2014). 
Molecular Findings Among Patients Referred for Clinical Whole-Exome 
Sequencing. JAMA, 312(18), 1870. https://doi.org/10.1001/jama.2014.14601 
Zablotsky, B., Black, L. I., Maenner, M. J., Schieve, L. A., Danielson, M. L., Bitsko, R. 
H., … Boyle, C. A. (2019). Prevalence and trends of developmental disabilities 




FEATURES INCLUDED IN EACH CATEGORY
Dysmorphic Features 
Short Stature Short stature 
Dysmorphic Facies 
Any mention of a feature of the face that is dysmorphic 
including forehead, eyes, nose, lips, chin, facial structure 
Cranium 
Microcephaly, macrocephaly, relative microcephaly, 
turricephaly, dolichocephaly, trigonocephaly, acquired 
microcephaly, plagiocephaly, narrow cranium, relative 
macrocephaly, borderline microcephaly 
High Arched Palate High arched palate 
Neck Short neck, wide neck, broad neck, torticollis 
Feet 
Short toes, 2-3 toe syndactyly, small feet, flat feet, toe 
contractures, abnormality of foot, sandal gap toes, webbing 
of toes, wideness of forefoot, pes planovalgus, broad great 
toes, brachydactyly, hypoplasia of the toes, dorsal puffiness 
of feet, splaying of toes 
Skeletal 
Bowing of lower legs, positional scoliosis, hip dysplasia, 
pectus carinatum, pectus excavatum, kyphoscoliosis, 
chondrodysplasia punctata, underdeveloped tibias, radial 
clubbing of hands, scoliosis, vertebral anomalies, low bone 
density 
Skin pigmentary changes 
Café au lait macules, mongolian spots, hypopigmented 
macules, skin changes, at birth pigment on legs, swirling 
pigmentation, vitiligo, ash leaf spot, variable pigmentation 
of the skin 
Tooth 
Tooth anomalies, dental anomalies, dental abnormalities, 
missing adult tooth, brittle teeth, diastema in central upper 
incisors, wide spaced teeth, small unusually shaped teeth 
Nail 
Nail anomalies, brittle nails, concave nails, deep-set nails, 




Small hands, short hands, stub thumbs, clinodactyly, single 
transverse palmar crease, bridge palmar crease, single 
palmer crease, horizontal crease on left hand, fetal fingertip 
pads, square-shaped thumbs, short metacarpal bones, 
camptodactyly, short metacarpals, short 5th finger(s), 
prominent fingertip pads, long thin tapered fingers, 
brachydactyly, hypoplastic thumbs, single flexion crease on 
5th fingers, adducted thumbs 
Hair 
Increased hair on back, thick eye brows, synophrys, 
abnormal hair pattern and growth, thin hair, low anterior 
hairline, sparse hair in parietal areas, sparse blonde hair, 
increased hair on arms, low anterior hairline, abnormal 
eyebrows 
Ears 
Low set ears, abnormal cartilage of external ears, 
preauricular tag, over-folded helices, large ears, mildly 
cupped ears, low set ears, dysmorphic ears, thick ear 
helices, dysplastic semicircular canals, misshapen right ear, 
posteriorly rotated ears, simple helices, left ear abnormality 
with prominent tragus/extra tissue, abnormally shaped ears, 




Penile torsion, undescended testes, shawl scrotum, 
penile chordee, hypoplastic labia, genital anomalies, 
cryptorchidism, hypospadias, small vaginal area, 
undescended testicle, small uterus with no 
connection of cervix to vagina, hypoplastic vagina 
Congenital heart defects (CHD) 
Patent foramen ovale, ventral septal defect, tricuspid 
valve defect, mild supravalvular aortic narrowing, 
atrial septal defect, left sided superior vena cava, 
congenital heart defect, patent ductus arteriosus, 
atrioventricular canal defect, coarctation of the aorta, 
short aortic arch, tetralogy of Fallot, aortic root 
dilation, left ventricular enlargement, small internal 
carotid artery, hypoplastic aortic arch 
Hernia 
Bilateral hernia, hernia, umbilical hernia, 
diaphragmatic hernia, inguinal hernia and hydrocoele 
Eye 
Chorioretinal colobomas, ocular anomalies, optic 
nerve hypoplasia, eye anomalies, hypoplasia of fovea 
centralis, optic nerve abnormalities, optic nerve 
atrophy, congenital macular scar, microphthalmia 
CL+/-P, uvula 
Submucosal cleft palate, bifid uvula, Pierre Robin 




Congenital brain anomalies, agenesis of corpus 
callosum, cerebellar dysplasia, enlarged cerebellum, 
enlarged vermis, small cysts, small peduncles, fused 
cerebellum, underdevelopment of left frontal lobe, 
dysgenesis of corpus callosum,  hypoplastic septum 
pellucidum, small corpus callosum, 
holoprosencephaly, cortical dysplasia, Dandy-
Walker variant, shortened corpus callosum, cerebral 
ventriculomegaly, polymicrogyria, cerebellar white 
matter abnormalities, periventricular leukomalacia 
(MRI in NICU), hemimegaloencephaly, 
interhemispheric brain cysts, cortical dysplasia, thin 
corpus callosum, brain malformations, small 
cerebellum, Chiari malformation, hydrocephalus, 
cerebral ventriculomegaly, cerebellar ectopia, 
periventricular leukomalacia found shortly after 
birth, agenesis of corpus callosum, polymicrogyria, 
midline arachnoid cyst, schizencephaly, heterotopias, 
brain stem underdevelopment, changes in cortical 
sulcation and opercularization patterns, 
spinocerebellar atrophy, craniosynostosis, cerebral 
atrophy, brain tumors 
Renal/Urinary Tract 
Surgery for ureter repair, hydronephrosis, small right 





Premature Born prior to 37w 
Thyroid Hypothyroidism, thyroid disease 
Other Eye 
Familial exudative vitreoretinopathy, heterochromia, 
chorioretinal scarring, photophobia, pupil dilation 
abnormalities, problems with tracking, lazy eye, retinal 
pigmentary changes, corneal abrasions 
Vision Loss 
Vision loss, retinopathy of prematurity, cortical vision 
impairment, severe myopia, visual impairment 
Skin Condition 
Eczema, dry skin, stretchy skin, dermal histiocytosis, 
irregular capillary vascular malformation of the skin, 
hemangioma, keratosis pilaris, soft skin 
Hearing Loss 
Hearing loss, auditory neuropathy, sensorineural hearing 
loss, conductive hearing loss 
49 
Metabolic Measures 
Electrolyte problems, concern for mitochondrial disorder, 
low blood glucose, selective IgA deficiency, ketotic 
hypoglycemia, mildly elevated CK, elevated plasma 
homocitrulline, elevated lactate, hyperlipidemia, 
hyperglycemia, mitochondrial abnormalities, vitamin d 
deficiency, mitochondrial abnormalities, metabolic 
abnormalities, elevated lactic acid, elevated alkaline 
phosphatase, mitochondrial dysfunction 
Cardiac Disease 
Dilated cardiomyopathy, heart murmur, mild cardiac 
hypertrophy, heart-left bundle block, heart murmur, 
bradycardia, mitral valve prolapse, postural orthostatic 
tachycardia syndrome 
Renal/Urinary 
Renal tubular acidosis, microscopic hematuria, vesicoureteral 
reflux, history of hydronephrosis, vesicoureteral reflux, 
chronic kidney disease, history of kidney issues and 
surgeries, kidney disease, neurogenic bladder 
Apnea History of apneic spells, sleep apnea, obstructive sleep apnea 
Pulmonary/Respiratory 
Asthma, pulmonary problems, chronic lung disease, choanal 
atresia, respiratory distress, velopharyngeal insufficiency, 
congenital hypoventilation syndrome, respiratory distress, 
asthma, recurrent respiratory infections, respiratory issues 
GI/GERD 
Gastroesophageal reflux disease, GI complications, 
constipation, recurrent intestinal obstruction, GI issues, 
delayed gastric emptying, eosinophilic esophagitis, chronic 
diarrhea, gastroparesis, gastrocutaneous fistula, 
gastrointestinal dysmotility, eosinophilic esophagitis 
Laryngomalacia Laryngomalacia 
Joint 
Hyperreflexia, joint pain, joint laxity, stiff joints, joint 
hypermobility, hyperreflexia, elbow stiffness, hyporeflexia, 
increased deep tendon reflexes, elbow laxity, 
hyperextensibility, progressive stiff joints, deep tendon 
reflexes, hyperreflexia, hyperextensibility, mild elbow 
stiffness 
Behavioral/Psychiatric 
Sensory processing issues, behavioral issues, anxiety, social 
anxiety, separation anxiety, self-injurious behaviors, 
obsessive compulsive disorder, head banging, depression, 
psychiatric concerns, bipolar disorder, oppositional defiant 
disorder, under-socialized conduct disorder, aggression, 
mental health issues 
Headaches Migraines, hemiplegic migraines, headaches 
Regression Any history of regression of skills 
Autism Diagnosis of autism spectrum disorder 





Any of the features listed in any of the other categories in 
this table 
Tone 
Hypotonia, hypertonia, low tone, mixed tone 
abnormalities 
Hypotonia Hypotonia 
Seizures Any history of seizures 
Eye Movement Disorders 
Abnormal eye movements, nystagmus, exotropia, 
esotropia, strabismus 
Coordination/Gait/Balance 
Unsteady gait, episodic ataxia, ataxia, abnormal 
ambulation, history of in-toeing, toe-walking, waddling 
gait, wide based gait, abnormal gait, mild gait imbalance, 
uncoordinated gait inability to walk, coordination 
impairment, poor balance, balance issues 
Abnormal Movements 
Jerky upper body movements, spasticity, abnormal 
twitching and jerking, abnormal movements, dystonia, 
clonus, spastic quadriplegia, infantile spasms, tremors in 
hands and feet, benign shuttering attacks 
Brain Condition 
Brain hemorrhage, white matter atrophy, abnormal brain 
MRI, leukodystrophy, brain cyst, cerebral atrophy, benign 
external hydrocephalus, hemimegaloencephaly, 
pseudotumor cerebri, delayed myelination, leukomalacia 
Staring Spells History of staring spells 
 
